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Role for Protein Kinase C-a in Keratinocyte Growth
Arrest
Anita Jerome-Morais1, Heidi R. Rahn1, Shalini S. Tibudan1 and Mitchell F. Denning1
Multiple protein kinase C (PKC) isoforms have been associated with the epidermal keratinocyte (KC) granular
layer differentiation program. Here we show PKCamembrane localization and substrate phosphorylation in the
first suprabasal KCs of normal human epidermis, suggesting activation in vivo in the lower spinous layers where
terminal differentiation-associated growth arrest occurs. To determine if PKCa is sufficient for KC growth arrest,
we expressed a constitutively active PKCa (PKCa D22–28) in normal human KCs and observed growth arrest and
accumulation of cells in G1. PKCa D22–28 inhibited DNA synthesis through the induction of the cyclin-
dependent kinase inhibitor p21. Furthermore, downregulation of PKCa in an in vitro organotypic epidermis
resulted in increased basal and suprabasal proliferation marker expression, decreased differentiation, and
reduced epidermal stratification. Together these results indicate that PKCa activation is both necessary and
sufficient to trigger irreversible growth arrest during human KC differentiation.
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INTRODUCTION
In normal interfollicular epidermis, only basal layer kerati-
nocytes (KCs) are in the cell cycle and capable of prolifera-
tion. These KCs express a specific complement of keratin (K)
intermediate filaments, composed primarily of K5 and K14
and have polarized expression of a6b4 integrin on their
basal surface. Upon commitment to differentiation, KCs
detach from the basement membrane, downregulate the
a6b4 integrin, irreversibly exit the cell cycle and begin the
stepwise differentiation program that eventually leads to the
formation of the cornified layer. The differentiation-asso-
ciated growth arrest that occurs upon exiting the basal layer is
efficient and irreversible, as isolated suprabasal KCs are
unable to attach or proliferate when placed into culture
(Peltonen et al., 1989; Adams and Watt, 1990; Tennenbaum
et al., 1996). The fidelity of this compartmentalized
proliferation under normal homeostasis is remarkable; how-
ever, aberrant suprabasal proliferation is observed during
wound healing and several disease states (Carroll et al., 1995;
Garlick et al., 1996; Crish et al., 2000). For example,
suprabasal proliferation is a hallmark of squamous-cell
carcinomas, indicating that the mechanisms regulating
normal commitment to irreversible growth arrest are faulty
in neoplastic KCs.
Protein kinase C (PKC) belongs to a family of serine/
threonine protein kinases that regulate a variety of biological
processes, including KC differentiation. The PKC family
consists of nine members, of which only five (a, d, e, Z, z)
are expressed in KCs (Denning, 2004). Classical PKC isoforms
(a) are calcium (Ca2þ ) dependent and novel PKC isoforms
(d, e, Z) are Ca2þ independent. Both classical and novel PKC
isoforms require diacylglycerol for activity, while atypical
PKC isoforms (z) are unable to bind to either Ca2þ or
diacylglycerol.
Several PKC isoforms (Z, d, a) have been implicated in the
KC differentiation program, especially granular layer differ-
entiation marker expression and cornification (Dlugosz and
Yuspa, 1993, 1994; Denning et al., 1995b; Lee et al., 1997;
Ohba et al., 1998; Deucher et al., 2002; Kashiwagi et al.,
2002; Papp et al., 2003; Seo et al., 2004). Extracellular Ca2þ
is a potent inducer of KC differentiation in cell culture, in
part, due to an elevation in intracellular Ca2þ , and while
multiple PKC isoforms translocate to the membrane fraction
in response to Ca2þ -induced KC differentiation, PKCa is the
only Ca2þ responsive isoform in KCs (Denning et al., 1995a).
In addition, a Ca2þ gradient exists in the epidermis, which is
postulated to play a role in the differentiation program. PKCa
can be more rapidly and preferentially activated than Ca2þ -
independent PKC isoforms in response to physiological,
phospholipase C coupled events such as KC differentiation
(Lenz et al., 2002). PKCa participates in the differentiation
program of mouse KCs by activating AP-1 transcription
factors in a Ca2þ -dependent manner (Rutberg et al., 1996).
The Ca2þ and TGFb-induced growth arrest in human KCs
requires the presence of PKCa (Sakaguchi et al., 2003,
2004), and PKCa was shown to be activated in a high-cell
See related commentary on pg 2330
& 2009 The Society for Investigative Dermatology www.jidonline.org 2365
ORIGINAL ARTICLE
Received 13 October 2008; revised 6 February 2009; accepted 14 February
2009; published online 2 April 2009
1Loyola University Medical Center, Cardinal Bernardin Cancer Center, Skin
Cancer Research Program, Maywood, Illinois, USA
Correspondence: Dr Mitchell F. Denning, Cardinal Bernardin Cancer Center,
Loyola University Medical Center, Skin Cancer Research Program, 2160 S.
First Avenue, Maywood, Illinois 60153, USA. E-mail: mdennin@lumc.edu
Abbreviations: Bis. I, bisindolylmaleimide I; Ca2þ , calcium; K, keratin; KC,
keratinocyte; MARCKS, myristolyated alanine-rich C kinase substrate;
PBPKC substrate, phosphorylated substrates of PKCa; PKCa D22–28,
constitutively active PKCa; ShRNA, small hairpin RNA; TPA,
12-O-tetradecanoyl phorbol 13-acetate
density-induced terminal differentiation (Lee et al., 1998).
PKC activation in general, and the activation of PKCa
specifically inhibits the expression of spinous layer markers,
and activates granular layer differentiation marker expression
in murine epidermal KCs (Dlugosz and Yuspa, 1993; Lee
et al., 1997).
Consistent with its prodifferentiation function, general PKC
activation with 12-O-tetradecanoyl-phorbol-13-acetate (TPA)
triggered an irreversible growth arrest in normal KCs. In
addition, suspension culture-induced irreversible growth
arrest was blocked by the general PKC inhibitor Bisindolyl-
maleimide I, Bis. I, as well as the inhibitor for classical PKC
isoforms, Go¨6976 (Tibudan et al., 2002). Suspension culture
also induced a specific increase in Ca2þ -dependent PKC
activity in KCs (Tibudan et al., 2002). PKCa has been
associated with growth arrest in other self-renewing biologi-
cal systems such as enterocytes and hematopoietic precursors
(Saxon et al., 1994; Frey et al., 1997, 2000; Hizli et al., 2006;
Nakagawa et al., 2006).
In this report we demonstrate that constitutively active
PKCa (PKCa D22–28) is sufficient to induce a G1 growth
arrest in normal human KCs, and that downregulation of
PKCa in organotypic raft cultures caused a delay in terminal
differentiation growth arrest resulting in increased basal and
suprabasal proliferation, as well as a defect in stratification.
These findings have uncovered a role for PKCa in the
differentiation-associated growth arrest of KCs, which to our
knowledge is previously unreported. As suprabasal prolifera-
tion is a hallmark of squamous-cell carcinomas, alterations in
PKCa expression and/or activation may be a contributing
factor to their altered response to differentiation signals.
RESULTS
PKCa is expressed and activated in the suprabasal layers of the
epidermis
To assess the expression pattern and localization of PKCa in
human epidermis, we performed immunostaining for total
PKCa protein in normal human foreskin sections. Figure 1
shows that PKCa was not detected in the basal layer of the
epidermis, but was expressed and membrane localized in the
suprabasal layers beginning with the first suprabasal or
spinous layer. The expression pattern of PKCa appears to be
biphasic, with initial low level membrane localization in the
spinous layers and high PKCa expression in the granular
layers, which appears to be both membranous and cytoplas-
mic. To determine if the membrane translocation of PKCa in
the differentiating layers of the epidermis was associated with
PKCa substrate protein phosphorylation in situ, we stained
normal human foreskin tissue sections with an antibody that
recognizes phosphorylated substrates of PKCa (PBPKC
substrate). This staining revealed that PKCa phosphorylated
substrates were localized in the suprabasal layers of the
epidermis and reached high levels in the granular layer, but
were excluded from the basal layer. Thus, the membrane
localization of PKCa in the spinous layers corresponds to
increased PBPKC substrate staining (Figure 1).
To ensure that the PBPKC substrate antibody recognized
only PKCa substrates, normal human KCs were retrovirally
infected with either control, PKCa (full length), PKCd, or
PKCa small hairpin RNA (shRNA) retrovirus and stained with
PBPKC substrate antibody (Figure S1). TPA treatment
increased PBPKC substrate staining in control cells, and
staining was further elevated when the PKCa overexpressing
cells were TPA treated. However, this increase was prevented
by downregulation of PKCa using shRNA, confirming that the
PBPKC substrate antibody is specific for PKCa substrates.
PKCd overexpressing cells did not show any higher PBPKC
substrate staining after TPA treatment (Figure S1).
Expression of PKCa D22–28 in KCs
To determine if activation of PKCa in normal human KCs is
sufficient to induce a growth arrest, we constructed a PKCa
D22–28 by deleting the pseudosubstrate domain from the
wild-type PKCa to generate PKCa D22–28. This deletion
should relieve the pseudosubstrate inhibition of the catalytic
domain making it constitutively active (Pears et al., 1990). To
confirm that PKCa D22–28 was indeed constitutively active,
we performed a membrane translocation assay. HaCaT cells
infected with PKCa D22–28 had a higher basal level of PKCa
associated with the membrane fraction compared with
control infected cells. For both control and PKCa D22–28
infected cells, the levels of membrane-associated PKCa
increased further on TPA treatment. In addition, the
phosphorylation of PKCa at the PDK1 phosphorylation site,
Ser 657, was increased when control cells were treated with
TPA. A similar increase in PBPKCa was observed with the
overexpression of PKCa D22–28, which was further elevated
after treatment with TPA (Figure 2b). Note that the amount of
membrane-associated PKCa was greater in the PKCa D22–28
expressing cells than TPA-treated control KCs, suggesting a
high level of constitutive PKCa D22–28 activation. PKCa
D22–28 also increased the levels of autophosphorylated
PKCa (Thr 638) and PBPKC substrates 18 hours after
transduction (Figure 2c).
To characterize the expression kinetics of PKCa D22–28, a
time course experiment was performed with human KCs
Total PKCα P~PKC substrate
Figure 1. PKCa is expressed and activated in the suprabasal layers of the
epidermis. Immunoperoxidase staining of normal human foreskin was
performed to visualize localization of total PKCa and phosphorylated PKCa
substrates (PBPKC substrate). Note the membrane localization of PKCa, and
the increased cytoplasmic PBPKC substrate staining in suprabasal KCs.
Staining was performed on five skin samples, and representative staining is
shown. Scale bar represents 10 mm.
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transduced with PKCa D22–28 or wild-type PKCa (Figure S2).
Wild-type PKCa expression increased progressively from 18
to 48 hours, whereas PKCa D22–28 levels increased at
18 hours, but remained constant and even decreased at later
time points (24–48 hours). The lower levels of PKCa D22–28
relative to wild-type PKCa may be due to negative selection
against cells expressing PKCa D22–28. The expression of
PKCa D22–28 had no reproducible effect on the expression of
PKCd.
PKCa inhibits KC proliferation
To determine the biological effects of PKCa activation,
normal human KCs were infected with PKCa D22–28 or
control Linker virus and counted 4 days after infection. The
number of control KC increased B12-fold over the 4-day
growth period; however, there was only B4-fold increase in
PKCa D22–28-expressing cells (po0.05). KCs infected with
control or PKCa D22–28 virus were also plated at a low
density and assayed for colony-forming efficiency. Control
infected cells had 54% colony-forming efficiency, whereas
only 12% of the KCs infected with the PKCa D22–28 formed
colonies (Figure 3b). The PKCa D22–28 significantly inhibited
DNA synthesis measured by 3H thymidine incorporation both
in cells that were not replated (Figure 3c) and in cells after
replating (Figure 3d). As reported previously, general PKC
activation by TPA treatment very effectively inhibited DNA
synthesis in replated and non-replated KCs (Tibudan et al.,
2002). Wild-type PKCa did not inhibit DNA synthesis when
the cells were maintained in the same dish, but did inhibit
DNA synthesis after replating. The decrease in thymidine
incorporation from 24 to 72 hours for the control KCs in
Figure 4c was due to the cells reaching confluence.
To determine whether active PKCa induces KC growth
arrest in a particular phase of the cell cycle, we performed
propidium iodide staining and flow cytometry. Constitutive
activation of PKCa caused the cells to arrest with 2N DNA
content in the G1 phase of the cell cycle at both 24 and
48 hours after infection (Figure 4a). Overexpression of the
PKCa D22–28 increased the G1/S ratio, whereas overexpres-
sion of the full-length PKCa in KCs did not have a significant
effect on cell cycle distribution (Figure 4a and b). The
expression of active PKCa did not induce apoptotic cells with
sub-G1 DNA content (Figure 4a). To further ensure that the
decrease in cell number was not due to increased apoptosis,
we performed annexin V staining, and did not see an increase
in the number of apoptotic cells after PKCa D22–28
expression (Figure 4c). Thus, the decrease in cell number
induced by active PKCa was due to G1 arrest, consistent with
terminal differentiation.
Induction of p21 by PKCa
The induction of the cyclin-dependent kinase inhibitor p21 is
an important component of the commitment to KC differ-
entiation (Topley et al., 1999). To determine if PKCa D22–28
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Figure 2. PKCa D22–28 is constitutively active. (a) Construction of the constitutively active PKCa D22–28 mutant. The pseudosubstrate domain of human PKCa
(amino acids 22–28) was deleted to generate the constitutively active PKCa mutant, PKCa D22–28. (b) PKCa translocation: HaCaT KCs were transduced with
either the empty vector LZRS-Linker (Control) or LZRS-PKCa D22–28 retroviruses and treated with 100 nM TPA for 30minutes as indicated. Membrane and
cytosolic fractionation was performed, and PKCa (arrows) and PBPKCa (Ser 657) were detected by western blotting. Similar results were obtained in one
additional experiment. (c) Phosphorylated PKC substrate levels: KCs were transduced with LZRS-Linker (Control) or LZRS-PKCa D22–28 retroviruses, protein
lysates after 18 hours were analyzed for total PKCa (arrow), the phosphorylation of PKCa substrates using the PBPKC substrate antibody and the
autophosphorylation of PBPKCa at Thr 638. Similar results were obtained in two additional experiments.
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expression in normal human KCs was sufficient to induce
p21, we infected KCs with either LZRS-Linker (Control) or
LZRS-PKCa D22–28 retroviruses and analyzed p21 protein at
24 and 48 hours. There was a transient upregulation of p21
(sevenfold) coinciding with the overexpression of PKCa
D22–28 at 24 hours (Figure 5a). In addition, TPA-induced
p21 was inhibited by the general PKC inhibitor (5 mM Bis. I)
and the PKCa inhibitor (5 mM Go¨6976) in normal human KCs
(unpublished data). Knockdown of p21 with small interfering
RNA (siRNA) reduced both basal and TPA-induced p21 levels
(Figure 5b), and prevented the reduction in DNA synthesis by
PKCa D22–28, but not TPA (Figure 5c).
To determine if overexpression of PKCa D22–28 was
sufficient to induce the complete KC differentiation program
in vitro, normal human KCs were infected with the active
PKCa D22–28 or Linker control retrovirus, and protein lysates
were run on western blots for differentiation marker analysis
(Figure S3). Overexpression of PKCa was confirmed at the 18,
24, and 36 hour timepoints, and PKCa activation was
confirmed based on autophosphorylation of PKCa at
Thr638 and phosphorylation of its downstream effector
myristolyated alanine-rich C kinase substrate, MARCKS
(Larsson, 2006). However, PKCa D22–28 was not sufficient
to induce any spinous (K1) or granular layer (Involucrin,
Loricrin, Caspase-14) differentiation markers in low Ca2þ
(0.07mM Ca2þ ) medium. K1, involucrin, loricrin, and
caspase 14 were all expressed in normal human skin, which
served as a positive control (Figure S3).
PKCa downregulation increases proliferation in organotypic
cultures
As PKCa was activated in the suprabasal layers of human
epidermis and active PKCa was sufficient to induce a G1
growth arrest in normal human KCs, we tested if the
downregulation of PKCa could either inhibit or delay the
irreversible growth arrest seen during normal KC differentia-
tion. We generated organotypic raft cultures using normal
human KCs by transducing with either a control shRNA or a
PKCa shRNA, plating KCs onto dermal equivalents, and
lifting to the air–liquid interface. KC differentiation was
assessed in the organotypic rafts 7 days after airlifting. We
verified that PKCa, but not PKCd, was downregulated to
B6% of control by the shRNA in monolayer cultures and in
organotypic raft epidermis by western blotting (Figure 6a).
When PKCa was downregulated in the organotypic raft
cultures, we noted that the epidermis occupied a larger
surface area on the dermal equivalent compared with the
control epidermis (Figure 6b).
Immunohistochemistry of the organotypic cultures with
antibodies against the proliferation markers Ki67 and PCNA
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Figure 3. Active PKCa inhibits KC proliferation. (a) Normal human KCs (105) were transduced with LZRS-Linker (Control) or the active PKCa D22–28
PKCa retrovirus. Cell counts were made 4 days after infection. Results are shown from three independent experiments (mean±SEM). (b) Normal human KCs
(105) were infected in quadruplicate with the control vector or active PKCa D22–28. After 2 days, 103 cells were then replated at a low density, cultured for
10 days, and colonies counted. Similar results were obtained in one additional experiment. (c–d) 3H Thymidine incorporation was used to measure DNA
synthesis in normal human KCs retrovirally transduced with the indicated viruses, or treated with TPA (10 nM) for 4 hours. (c) Shows thymidine incorporation of
cells that were not replated. The inhibition of DNA synthesis by PKCa D22–28 without replating was significantly different than the control (* denotes Po0.01)
at 24, 48, and 72hours. (d) Shows thymidine incorporation after replating at low density. The inhibition of DNA synthesis by PKCa D22–28 after replating
was significantly different from control (# denotes Po0.001) at 72 and 96 hours. Results are shown from seven independently infected/treated wells
(mean±SD). Similar results were obtained in three additional experiments.
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showed that proliferation was restricted to the basal layer in
the control shRNA cultures. Downregulation of PKCa caused
increased basal and suprabasal proliferation marker expres-
sion in the epidermis (Figure 7a and 7b). Thus, PKCa is
partially required for differentiation-associated growth arrest
in differentiating KCs, and the loss of PKCa delays
growth arrest. Downregulation of PKCa did not protect KCs
from growth arrest induced by other differentiation
stimuli; confluency, TPA, and suspension in methylcellulose
(Figure S4). However, the general PKC inhibitor Bis. I did
protect from suspension-induced growth arrest, even in KCs
with PKCa downregulated, implicating other PKC isoforms or
even non-PKC signals in triggering growth arrest by these
differentiation stimuli.
Although there was increased proliferation when PKCa
was downregulated, hematoxylin and eosin staining showed
that PKCa shRNA organotypic raft epidermis were signifi-
cantly (Po0.05) thinner than the control shRNA epidermises
(Figure 7c). The decreased epidermal thickness despite
increased proliferation was surprising, and could be due to
an alteration in migration/stratification, or a compensatory
increase in apoptosis in the PKCa downregulated organotypic
raft epidermises. KCs in submerged monolayer cultures
lacking expression of PKCa did not show any increase in
apoptosis as determined by annexin V staining, and there was
also no increase in the number of apoptotic cells in the
organotypic raft epidermis with PKCa downregulated com-
pared with the control epidermis, as determined by the
TUNEL assay (Figure S5). Thus, increased apoptosis cannot
account for the epidermal hypoplasia in PKCa shRNA
organotypic cultures.
Immunohistochemical localization of differentiation mar-
ker expression in control and PKCa shRNA organotypic
cultures showed that PKCa shRNA cultures had increased
early differentiation marker expression (K1) and decreased
late granular layer differentiation marker (loricrin) (Figure 7d),
consistent with the previously characterized role for PKC
in KC differentiation (Dlugosz and Yuspa, 1993, 1994;
Denning et al., 1995b; Lee et al., 1997; Ohba et al., 1998;
Deucher et al., 2002; Kashiwagi et al., 2002; Papp et al.,
2003; Seo et al., 2004).
DISCUSSION
The roles of PKC and its specific isoforms in epidermal
differentiation marker expression have been extensively
studied, and it is well established that multiple PKC isoforms
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Figure 4. Active PKCa induces G1 accumulation without increased apoptosis. (a) Normal human KCs were infected in duplicate with LZRS-Linker (Control),
active PKCa D22–28, or PKCa retroviruses and harvested after 1 and 2 days. Propidium iodide staining and flow cytometry to analyze cell cycle distribution
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after 3 days. Shown is the mean±range (N¼2) from one experiment. Similar results obtained in one additional experiment.
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become activated in a variety of in vitro KC differentiation
model systems (Denning et al., 1995a, 1995b; Stanwell et al.,
1996). Chemical activators such as phorbol esters have been
widely used, but have significant non-PKC effects and are not
PKC isoform specific, even when used on cells overexpres-
sing a particular PKC isoform (Oliva et al., 2008). The focus
of this paper was to study the function of PKCa in normal
human KCs using both gain-of-function and loss-of-function
genetic approaches with particular emphasis on determining
the role of PKCa in KC growth arrest. We showed that the
expression of a constitutively activated PKCa D22–28 in
normal human KCs inhibited growth and DNA synthesis by
inducing a G1 arrest in a p21-dependent manner. Wild-type
PKCa overexpression, however, did not cause a significant
inhibition of DNA synthesis without replating (Figure 3d). We
have observed that KCs are much more sensitive to TPA-induced
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LZRS-PKCa D22–28 retrovirus. Protein was isolated for western blotting at both the 24- and 48-hour time points. p21 was transiently upregulated at the protein
level at the 24 hour time point. The arrow denotes PKCa. Similar results were obtained in two additional experiments. (b) Control or p21 siRNA oligonucleotides
were used to transfect normal human KCs. After 24 hours, KCs were infected with either LZRS-Linker (Control) or LZRS-PKCa D22–28 retrovirus. Cells were
treated with 100 nM TPA for 4 hours the next day, after which protein was isolated to be analyzed by western blotting. Note that p21 siRNA oligos downregulated
p21 in KCs. Similar results were obtained in two additional experiments. (c) KCs were transfected with the control and p21 siRNA
oligos and then retrovirally transduced with either LZRS-Linker (Control) or PKCa D22–28 retrovirus. Twenty-four hours after infection, DNA synthesis was
measured using 3H thymidine incorporation. Note that PKCa activation caused an inhibition of DNA synthesis in the control siRNA cells, but not in cells
where p21 is downregulated. The KCs treated with 10 nM TPA for 1 hour was used as a positive control for inhibition of DNA synthesis. Shown are the
mean±SD. Similar results were obtained in two additional experiments.
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were obtained in four additional experiments.
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growth arrest at low density (data not shown). As the non-
replated KCs are at relatively high density, the lower activity
of the wild-type PKCa may not be sufficient to induce growth
arrest in the non-replated cells. Other PKCs, such as PKCZ,
are capable of inducing KC growth arrest, but the expression
of PKCZ is localized to the granular layer (Cabodi et al.,
2000) not in the spinous layer where growth arrest occurs in
the epidermis. One possible scenario is that PKCa induces
the growth arrest in KCs during early spinous differentiation,
and PKCZ is required to maintain that growth arrest in the
epidermis. Indeed, the epidermis of PKCZ-null mice has
prolonged hyperplastic response to wound healing (Chida
et al., 2003).
To determine if PKCa was activated in the appropriate
epidermal tissue compartment, we sought in vivo evidence
for PKCa activation in the first suprabasal or lower spinous
layers in human epidermis. On the basis of immunostaining,
we found that PKCa was not only expressed in the first
suprabasal layers of skin, but was also membrane trans-
located and became activated in these layers (Figure 1). The
suprabasal and membrane localization of PKCa in the human
epidermis has been described previously, although the
precise layer of activation was not defined (Tibudan et al.,
2002; Denning, 2004; Cataisson et al., 2006). Extensive
characterization of a PBPKC substrate antibody demon-
strated that this reagent reacts against KCs only when PKCa
is present and activated (Figure S1). The reactivity of this
PBPKC substrate antibody was reduced in KC overexpressing
PKCd and treated with TPA. This may represent a negative
feedback or reflect competition for TPA by the overexpressed
PKCd. Other PKC isoforms implicated in KC differentiation
have unique localization patterns by immunostaining in the
epidermis. PKCd is expressed throughout the epidermis, and
there was no evidence of differentiation-associated activation
based on localization (D’Costa et al., 2006). PKCZ has been
localized to the granular layer by immunostaining, and it is
not expressed in the proper tissue compartment to initiate
growth arrest (Koizumi et al., 1993).
The mechanism for PKCa-induced growth arrest has been
studied in KCs treated with various stimuli and in other cell
systems. PKCa overexpression and TPA treatment induces a
G1 arrest in the intestinal epithelial cells by activating the
extracellular signal-regulated kinase signaling cascade, Rb
hypophosphorylation, induction of p21/p27 cdk inhibitors,
and inhibiting translation of cyclin D1 (Frey et al., 1997,
2000; Hizli et al., 2006). Although transient extracellular
signal-regulated kinase signaling leads to cell cycle progres-
sion, sustained extracellular signal-regulated kinase activa-
tion leads to growth arrest and differentiation in these cells
(Clark et al., 2004). PKCa activation also arrested pancreatic
cancer cells in G1, due to induction of p21, which resulted in
selective inhibition of cdk2 activity with hypophosphoryla-
tion of Rb (Detjen et al., 2000). Retinoic acid-induced growth
arrest in breast carcinoma cells requires expression of PKCa
(Cho et al., 1997). Both Ca2þ - and TGFb-induced growth
arrest in KCs require PKCa and S100C to increase p21
(Sakaguchi et al., 2005). p21-null KCs resist the growth
arresting effects of Ca2þ (Missero et al., 1996).
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Figure 7. Downregulation of PKCa resulted in decreased epidermal
thickness and increased basal/suprabasal proliferation. (a) Organotypic
cultures of KCs transduced with control shRNA or PKCa shRNA viruses were
generated. Hematoxylin and eosin staining of the organotypic raft epidermis
showed decreased epidermal thickness when PKCa was downregulated.
Immunofluorescent staining showed increased basal and suprabasal
expression of the proliferation markers Ki67 and PCNA in the PKCa shRNA
cultures. Scale bar represents 10 mm. (b) Quantification of the basal and
suprabasal expression of Ki67 and PCNA. Note increased basal and
suprabasal proliferation markers in PKCa shRNA cultures. Similar results were
obtained in three additional experiments. (c) Quantification of the epidermal
thickness in control and PKCa downregulated organotypic raft epidermises.
Data are average of three independent experiments, with error bars denoting
SD. (d) Analysis of the spinous differentiation marker expression (K1)
and granular layer differentiation marker expression (Loricrin) by
immunofluorescence staining of the raft epidermis. Note reduced K1
and increased loricrin expression in shPKCa organotypic culture. Similar
results were obtained in four additional experiments. Scale bar represents
10mm.
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Downregulation of p21 using siRNA blocked the ability
of PKCa D22–28 to inhibit DNA synthesis, implicating the
upregulation of p21 in PKCa-mediated growth arrest
(Figure 5). However, transfection of KCs with p21 siRNA
also decreased the basal thymidine incorporation level,
which suggests a role for the cyclin-dependent kinase
inhibitor, p21 in cell cycle progression (Figure 5c). p21 was
previously shown to play a role in cell cycle progression by
promoting the association of cyclin D1 and Cdk4 and
enhancing the nuclear import of cyclin D1 (LaBaer et al.,
1997; Cheng et al., 1999; Coqueret, 2003).
Consistent with PKCa activation-induced growth arrest,
the downregulation of PKCa in organotypic raft cultures
showed increased basal and suprabasal proliferation. In
addition to the increased proliferation, there was decreased
epidermal thickness in the PKCa downregulated raft (Figure
7a and b) suggesting a role for PKCa in stratification during
differentiation. Mice null for PKCa had reduced epidermal
thickness after wound healing, although the non-wounded
epidermis had normal proliferation and differentiation
marker expression (Hara et al., 2005). The lack of increased
epidermal proliferation in PKCa-null mice may be due to
compensation by the other PKC isoforms. There was
enhanced tumor formation in the PKCa-null mice in the
two-stage chemical skin carcinogenesis model consistent
with a tumor suppressor function for PKCa. The suprabasal
proliferation and the inability of the cancer cells to respond
to differentiation stimuli is a hallmark of cancer, and the
lack of PKCa activation in squamous-cell carcinoma cell
lines could be responsible for the delay in irreversible
growth arrest and thus increased suprabasal proliferation
(Yang et al., 2003).
Although the organotypic raft culture epidermis with
downregulated PKCa had enhanced proliferation, there was
also a consistent and unexpected decrease in epidermal
thickness. We ruled out increased apoptosis, but there are
many other possible explanations for the decreased
epidermal thickness in the absence of PKCa. There was
decreased granular differentiation and defective spinous layer
differentiation, which may impede stratification of the rafts
(Figure 7d). Other possibilities include an increase in
cell–matrix adhesion, resulting in the larger surface area
occupied by the epidermis (Figure 6b), or altered migration
potential of the differentiating KCs, with either increased
lateral migration or decreased suprabasal migration produ-
cing the wider and thinner PKCa shRNA organotypic
epidermis observed. A role for PKCa in migration has been
described previously in human hepatocellular carcinoma
cells (Hsieh et al., 2007; Wu et al., 2006, 2008), urinary
bladder carcinoma cells (Koivunen et al., 2004), and in
endothelial cells (Harrington et al., 1997; Bokhari et al.,
2006). We have also observed reduced migration of KCs with
downregulated PKCa in a monolayer scratch assay (data not
shown). Another possible explanation for the thinner
epidermis could be due to weaker cell–cell adhesion,
resulting in enhanced desquamation in the PKCa shRNA
stratified epithelia. PKCa subcellular localization has been
correlated with desmosome formation in KCs (Wallis et al.,
2000), and PKCa has been localized to the tight junction–-
desmosome complexes in the intact mouse epidermis (Jansen
et al., 2001). However, we did not observe a thinner stratum
corneum in the PKCa shRNA organotypic cultures. Thus, the
most likely explanation for the thinner epidermis is reduced
cell migration and differentiation.
In summary, PKCa induces a differentiation-associated
growth arrest and inhibition of DNA synthesis in normal
human KCs. Downregulation of PKCa in the epidermis of
organotypic raft cultures delayed the growth arrest, thus
expanding the basal proliferating layer resulting in increased
basal and suprabasal proliferation. In agreement with
previous studies, we also found that PKCa is important for
granular layer differentiation (Lee et al., 1997; Papp et al.,
2003). Therefore, PKCa plays a dual role in early differentiation,
by inducing differentiation-associated growth arrest in the
spinous layer and also suppressing spinous marker expression.
MATERIALS AND METHODS
Antibodies and chemicals
The PKC inhibitor Bis. I (GF109203X) and the phorbol ester, 12-O
tetradecanoyl-phorbol-13-acetate (TPA) were purchased from Alexis
Biochemicals (San Diego, CA). The chemicals were dissolved in
DMSO.
For detection of PKCa, the monoclonal PKCa antibody (05–154)
from Upstate Biotechnology Inc. (Lake Placid, NY) or the polyclonal
rabbit antibody (sc-208) from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA) was used. The antibodies detecting differentiation markers
Loricrin (PRB-145P) and K1 (PRB-149P) were from Covance Inc.
(Princeton, NJ). Involucrin (sc-21748), Caspase-14 (sc-5628), PCNA
(sc-7907), PKCd (sc-937), MARCKS (sc-6454) antibodies were from
Santa Cruz Biotechnology Inc. The p21 (2947), PBPKC substrate
(2261), PBPKCa Thr 638 (9375), and PBMARCKS (2741) anti-
bodies were from Cell Signaling (Beverly, MA). The PBPKCa Ser
657 antibody (06–822) was from Upstate Biotechnology Inc. The
antibodies for the detection of the proliferation markers Ki67
(M7240) and PCNA (610664) were obtained from DAKO (Glostrup,
Denmark) and BD Biosciences (San Diego, CA), respectively.
Cell culture
Normal human epidermal KCs were isolated from foreskins after
routine circumcision following the Loyola IRB guidelines and
cultured in Medium 154 with EKGS (Cascade Biologics, Portland,
OR) containing 0.07mM Ca2þ as described previously (Mitra and
Nickoloff, 1994; Tibudan et al., 2002). Immortalized HaCaT KCs
were also cultured in Medium 154 containing 0.07mM Ca2þ .
Phoenix-Ampho cells (ATCC, Manassas, VA; with permission from
Garry P. Nolan, Stanford University Medical Center) were cultured
in DMEM and 10% fetal bovine serum.
Colony-forming assay was performed as described previously
(Tibudan et al., 2002). DNA synthesis in KC cultures was measured
by 3H-thymidine incorporation as described previously (Tibudan
et al., 2002).
For the p21 downregulation experiments, siRNA oligos
were transfected into normal human KCs using Oligofectamine
(Invitrogen, Carlsbad, CA). The control siRNA oligos (1027281) and
p21 siRNA oligos (SI00604905) were purchased from Qiagen Inc.,
Valencia, CA.
2372 Journal of Investigative Dermatology (2009), Volume 129
A Jerome-Morais et al.
Role for PKCa in Keratinocyte Growth Arrest
Immunostaining of tissue sections
Immunohistochemical and immunofluorescent staining of formalde-
hyde-fixed paraffin-embedded sections, organotypic raft, or skin
tissue was performed as per the manufacturer’s instructions (Vector
Laboratories, Burlingame, CA and Molecular Probes, Eugene, OR)
with minor modifications. Images from slides were taken with
Olympus AX80 fluorescence microscope equipped with Mono-
chrome Retiga 4000R 4.2 MPixel camera and RGB Color Filter.
Retrovirus production
Retroviruses encoding shRNA were constructed using the pSUPER.-
retro.puro vector system (OligoEngine, Seattle, WA). A double-
stranded hairpin oligonucleotide designed to target the human PKCa
cDNA nucleotides (AGGCUGAGGUUGCUGAUGA) was cloned
into pSUPER.retro.puro (Irie et al., 2002). A control shRNA virus was
constructed, which encoded a 19-bp target sequence (GCGCGCTT
TGTAGGATTCG), with no significant homology to any gene in the
human genome. Correct insertion of the oligonucleotides was
confirmed by DNA sequencing.
The human full-length PKCa cDNA was obtained from ATCC (no.
65978, Manassas, VA), and cloned into the EcoRI site of the
retroviral vector LZRS-Linker to generate the wild-type PKCa vector,
LZRS-PKCa. To generate the PKCa D22–28, the pseudosubstrate
domain was deleted (amino acids 22–29) using the site-directed
mutagenesis (Quickchange Site-Directed Mutagenesis kit, Strata-
gene, La Jolla, CA), and cloned into the EcoRI site of LZRS-Linker to
generate LZRS-PKCaD22–28 (Pears et al., 1990). The deletion was
verified by DNA sequencing. Retroviruses were produced in
Phoenix-Ampho packaging cells by Ca2þ phosphate transfection
and selection with 1mg/ml puromycin as described previously
(Kinsella and Nolan, 1996).
Western blotting
Western blotting was performed as described previously with some
variations (Tibudan et al., 2002). The membrane was blocked using
the Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, Nebras-
ka) and stained with primary and fluorescent-labeled secondary
antibodies. The protein bands were detected using the Odyssey
Infrared Imaging System (LI-COR Biosciences). Cell fractionation
was performed as described previously (Denning et al., 1995b).
Organotypic raft culture
Keratinocytes used for the organotypic raft cultures were infected
with either control shRNA or PKCa shRNA retrovirus and grown in
subconfluent monolayers in the presence of 1mg/ml puromycin to
select for retroviral infection. Organotypic raft cultures were
generated based on the protocol described by Meyers et al. (1994).
The dermal equivalent was made with 105 J2–3T3 fibroblasts or
normal human fibroblasts per ml of collagen (Collagen Type I rat tail,
3.79mg/ml BD Biosciences, Bedford, MA) with or without cell
culture inserts (1.0 mm pore size, PET track-etched membrane, cat.
no. 353103, Becton Dickinson Lab, Franklin Lakes, NJ). Twenty-four
hours after making the collagen plug, 2 106 control shRNA or
PKCa shRNA KCs were plated on top of the plug in E-media with
5 ng/ml EGF. After 7 days, airlifting rafts were fixed in buffered
formalin (Fisher Scientific, Kalamazoo, MI) or the epidermis
removed for protein isolation and western blotting. The epidermal
thickness was calculated from three independent experiments using
a micrometer. Three measurements of the viable layers were taken
from each individual experiment. Quantitation of the proliferation
markers Ki67 and PCNA was performed by counting positive cells
per 20 field.
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Table S2. Expression kinetics of PKCa and PKCa D22-28.
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